NCT04414930CompletedPhase 2
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
These studies look to conduct efficient pilot testing of a novel intervention strategy for chronic psychotic disorders - Pharmacologic Augmentation of Cognitive Therapy (PACT) - via an experimental medicine approach. Antipsychotics are the major therapeutic tool for chronic psychotic disorders, including schizophrenia, but do not significantly alter their course or real-life impact. Specific cognitive therapies achieve modest symptom reduction and improved function and cognition in psychosis patients, including "bottom-up" sensory-based targeted cognitive training (TCT). While benefits of TCT are evident at the group level, almost half of all patients demonstrate little or no cognitive gains after 30-40 hours (h) of TCT. For patients and clinicians, the costs and logistical complexities associated with these time- and resource-intensive interventions can be prohibitive. We propose and will test a novel "augmentation strategy" for using medications to specifically enhance the benefits of TCT in schizophrenia.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 68 (actual)
- First submitted
- 22 May 2020
- Start date
- 9 Nov 2020
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- University of California, San Diego
- Diseases
- Schizophrenia
- NCT number
- NCT04414930
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 68
- From 9 Nov 2020 to the primary completion date, 30 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- A history of traumatic brain injury
Other
- Meets DSM-IV criteria for current substance abuse or dependence and has been substance abstinent for less than 30 days
- Auditory or visual impairments severe enough to prevent study participation
- Under conservatorship (determined by Anasazi)
- Pregnancy
Who the study is looking for
- DSM-IV diagnosis of schizophrenia or schizoaffective disorder, depressed type
- Written informed consent to participate in the study
- Age 18 - 55
- Absence of dementia or mental retardation
- Urine toxicology negative for recreational drugs
- Fluent and literate in English (needed for completion of WIN and QuickSIN)
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinical Teaching Facility (CTF-B102) at UCSD Medical Center Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.